Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–185 of 185 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Emtricitabine 200 MG Clear all
Terminated Phase 4 Interventional Results available

Dolutegravir in Reservoirs

NCT02924389
View directory record Official record
Conditions
HIV
Interventions
dolutegravir, Triumeq, Truvada
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

NCT02431247
View directory record Official record
Conditions
Immunodeficiency Virus Type 1, Human
Interventions
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
18 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 4 Interventional Results available

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

NCT00762892
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and truvada, Atazanavir, Norvir and Truvada
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

NCT01403051
View directory record Official record
Conditions
HIV-1 Infection
Interventions
EFV/FTC/TDF, Calcium Carbonate, Vitamin D3, Placebo for calcium carbonate, Placebo for vitamin D3
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

NCT04692077
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, CAB LA, Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 17 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Botswana TDF/FTC Oral HIV Prophylaxis Trial

NCT00448669
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 39 Years
Enrollment
1,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

NCT03836729
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir alafenamide/emtricitabine, GSK3640254
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

NCT03917420
View directory record Official record
Conditions
HIV/AIDS
Interventions
Tenofovir 300Mg Oral Tablet, Emtricitabine 200 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil

NCT00307489
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
tenofovir DF, emtricitabine /tenofovir DF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
San Francisco, California • San Jose, California • Flushing, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy

NCT04050371
View directory record Official record
Conditions
HIV Prevention, Transgender Health
Interventions
200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

NCT01854775
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
E/C/F/TAF, E/C/F/TAF (Low Dose)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

NCT00458393
View directory record Official record
Conditions
HIV Infections
Interventions
daily TDF/FTC, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

NCT01705574
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
41
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

NCT02345226
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

NCT04143594
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
49
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

NCT03048422
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz/emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV

NCT02401230
View directory record Official record
Conditions
HIV
Interventions
Truvada, Gel lubricant
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 9, 2026, 10:47 PM EDT